Emilie R Elliot
Overview
Explore the profile of Emilie R Elliot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
61
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Elliot E, Polli J, Patel P, Garside L, Grove R, Barnett V, et al.
J Infect Dis
. 2024 Jul;
230(1):e34-e42.
PMID: 39052748
Background: Cabotegravir plus rilpivirine (CAB + RPV) is a guideline-recommended long-acting (LA) injectable regimen for the maintenance of human immunodeficiency virus-1 (HIV-1) virologic suppression. This post hoc analysis summarizes CAB...
2.
Elliot E, Neary M, Else L, Khoo S, Moyle G, Carr D, et al.
J Antimicrob Chemother
. 2020 Feb;
75(5):1259-1266.
PMID: 32011683
Objectives: Dolutegravir has replaced efavirenz as first-line treatment in universal HIV guidelines. We sought to ascertain the contributory effect of SNPs in four key genes linked to dolutegravir disposition (UGT1A1,...
3.
Elliot E, Bisdomini E, Dilly Penchala S, Khoo S, Nwokolo N, Boffito M
HIV Res Clin Pract
. 2019 Jul;
20(3):82-91.
PMID: 31335301
Access to safe and reliable contraception in the context of ARVs is essential. This study aimed to investigate the steady-state pharmacokinetics (PK) of ethinylestradiol/levonorgestrel (EE/LNG) 30/150 μg (Microgynon) and atazanavir/cobicistat...
4.
Elliot E, Cerrone M, Challenger E, Else L, Amara A, Bisdomini E, et al.
J Antimicrob Chemother
. 2019 Feb;
74(5):1466.
PMID: 30778557
No abstract available.
5.
Elliot E, Cerrone M, Challenger E, Else L, Amara A, Bisdomini E, et al.
J Antimicrob Chemother
. 2018 Oct;
74(1):149-156.
PMID: 30272231
Background: Dolutegravir combined with darunavir/cobicistat is a promising NRTI-sparing and/or salvage strategy for the treatment of HIV-1 infection. Methods: This Phase I, open-label, 57 day, crossover, pharmacokinetic (PK) study, enrolled...
6.
Elliot E, Wang X, Singh S, Simmons B, Vera J, Miller R, et al.
Clin Infect Dis
. 2018 May;
68(1):87-95.
PMID: 29771285
Background: Demographic data show an increasingly aging human immunodeficiency virus (HIV) population worldwide. Recent concerns over dolutegravir-related neuropsychiatric toxicity have emerged, particularly amongst older people living with HIV (PLWH). We...
7.
Elliot E, Amara A, Pagani N, Else L, Moyle G, Schoolmeesters A, et al.
J Antimicrob Chemother
. 2017 May;
72(7):2143.
PMID: 28482097
No abstract available.
8.
Elliot E, Amara A, Pagani N, Else L, Moyle G, Schoolmeesters A, et al.
J Antimicrob Chemother
. 2017 Apr;
72(7):2035-2041.
PMID: 28407075
Background: We investigated the pharmacokinetics (PK) of atazanavir/cobicistat and darunavir/cobicistat once daily over 72 h following drug intake cessation in plasma, saliva and urine. Methods: Healthy volunteers received a fixed-dose...
9.
Elliot E, Theodoraki A, Jain L, Marshall N, Boffito M, Baldeweg S, et al.
Clin Med (Lond)
. 2016 Oct;
16(5):412-418.
PMID: 27697800
Ritonavir and cobicistat, used as pharmacokinetic enhancers in combination with some antiretrovirals (ARVs) for the treatment of HIV, are potent inhibitors of the CYP3A4 isoenzyme. Most glucocorticoids are metabolised via...